National Peroxide Limited Overview
| Field | Detail | Source / Year |
|---|---|---|
| Legal name | National Peroxide Limited | BSE listing notice, 2 Jul 2024 |
| Former name | NPL Chemicals Limited (until fresh certificate dated 31 Jan 2024) | IIFL company summary; BSE filings |
| Incorporation of current legal entity | 29 July 2020 (Certificate of Incorporation dated 5 Aug 2020), RoC Maharashtra, Mumbai | IIFL company summary |
| Heritage / founding of business | 1954, as a joint venture of the Wadia Group (Bombay Dyeing) and Laporte Industries, UK | Solvay press release, 28 Mar 2017 |
| Predecessor legal entity | Original National Peroxide Limited (CIN L66309MH1954PLC009254), renamed Naperol Investments Limited on 28 Dec 2023; BSE 500298 | Naperol filings, Jan 2025 |
| Incorporation jurisdiction | Maharashtra, India (Companies Act, 2013) | IIFL / BSE |
| Registered office | Neville House, J. N. Heredia Marg, Ballard Estate, Mumbai 400 001; Tel. +91-22-6662 0000 | Emkay company info, 2026 |
| Investor contact | investorrelations@naperol.com | Emkay company info, 2026 |
| Manufacturing site | Kalyan (Thane district), Maharashtra | Company summaries |
| Stock exchange & ticker | BSE Ltd — scrip code 544205 (Group B); not listed on NSE | BSE notice 20240702-22; ICICIdirect |
| Listing date | Admitted to dealings on BSE effective 4 July 2024 | BSE notice, 2 Jul 2024 |
| ISIN | INE0PO601011 | MarketsMojo / Emkay |
| CUSIP | Not applicable (Indian security; no US listing) | — |
| Face value / shares outstanding | ₹10 per share; 57,47,000 (5.747 million) equity shares; paid-up capital ₹5.75 Cr | Allotment intimation, 27 Sep 2023 |
| Registrar & transfer agent | MUFG Intime India Pvt. Ltd., Vikhroli (W), Mumbai | Emkay company info |
| Fiscal year end | 31 March | Filings |
| Employees (latest) | 124 (S&P, 2026) / 128 (Simply Wall St, 2026) — small discrepancy between aggregators; 3-year trend not publicly disclosed in sources reviewed | StockAnalysis; Simply Wall St |
| Statutory auditor | — | — |
| Market capitalisation | ≈ ₹336 Cr (₹3.36 bn) at ₹585.05 close on 6 Oct 2026; enterprise value ≈ ₹277 Cr | S&P via StockAnalysis, 6 Oct 2026 |
| Website | www.naperol.com | Company filings |
| Group affiliation | Wadia Group (Nowrosjee Wadia & Sons, Bombay Burmah Trading Corp., Bombay Dyeing, Britannia) | Wadia Group website |
| Promoter holding | 70.76% (30 Jun 2026) | Shareholding filings |
The entity profiled is National Peroxide Limited (NPL), Mumbai, India — the operating hydrogen peroxide business of the Wadia Group, listed on BSE under scrip code 544205. The type supplied ("Public company") is correct: NPL is a listed public limited company, though a micro-cap with a very small free float.
National Peroxide Limited is a single-site, single-product commodity chemical company and, by its own and widely repeated description, India's largest producer of hydrogen peroxide (H₂O₂). From one integrated complex at Kalyan, Maharashtra — with nameplate capacity of 150,000 MTPA on a 50% w/w basis after a ₹200 Cr expansion commissioned in early 2020 — it supplies technical- and food-grade H₂O₂ in 35%–70% concentrations, alongside by-product compressed hydrogen gas and peracetic acid, to textile, pulp and paper, chemical, refinery effluent-treatment, mining, electronics, pharmaceutical and food customers. Founded in 1954 as a Wadia–Laporte joint venture, the business was carved out of its historic legal shell in 2023 and relisted in July 2024. It is effectively debt-free, carries substantial treasury investments, and trades below book value; however, profitability is highly cyclical and import-exposed, with net margins of –0.8% to 10.5% over FY2023–FY2026 and a recent restatement of audited FY2026 results.
What the company does
NPL manufactures hydrogen peroxide using the anthraquinone auto-oxidation (AO) process, the global industry-standard route. In this process, an anthraquinone "working solution" is hydrogenated, then oxidised with air; the oxidation releases H₂O₂, which is extracted with water, purified and concentrated, while the anthraquinone is regenerated and recycled. The key variable inputs are hydrogen (NPL produces its own from natural gas in a captive hydrogen plant first established in 1987, supported by a long-term gas supply agreement with GAIL (India) Ltd), power, anthraquinone/working-solution chemicals and solvents, and packaging. Surplus hydrogen is compressed and sold as compressed hydrogen gas, and H₂O₂ is reacted with acetic acid to produce peracetic acid, a disinfectant and sterilant.
Company descriptions (repeated in exchange summaries and the FY2021 annual report of the predecessor) characterise NPL as having pioneered peroxygen chemicals in India and as the country's largest H₂O₂ manufacturer. The standard commercial product is a 50% w/w aqueous solution; 35%, 60% and 70% concentrations are also produced, in technical and food grades.
Business model and revenue model
| Revenue model element | Characterisation |
|---|---|
| Product vs service vs subscription vs licensing mix | ~100% product sales (commodity chemical manufacturing). No service, subscription or licensing revenue disclosed. |
| Pricing basis | Spot and contract pricing set largely by domestic supply–demand and landed import parity (South-East Asia, Bangladesh, Korea, Taiwan and others). |
| Sales channel | Direct sales to industrial users and distributors, in bulk tankers (typically 20–25 t) and carboys; exact channel mix not publicly disclosed. |
| Cost structure | Raw materials were ₹141–246 Cr p.a. (49%–66% of sales) in FY2023–FY2026; energy/natural gas is a major component of "other expenses"; employee cost only ₹26–30 Cr p.a. (~9% of sales) reflecting a highly automated continuous-process plant. |
| Capital intensity | Gross machinery block ≈ ₹415 Cr against annual sales of ₹290 Cr (FY2026); depreciation ≈ ₹20–21 Cr p.a. |
Value-chain position
NPL sits in the intermediate commodity-chemicals layer: it converts natural gas (via hydrogen) and air into an oxidant that is consumed by downstream processors. It does not formulate consumer products. Upstream, it depends on GAIL for natural gas and on chemical suppliers for working-solution components; downstream, it competes for share of customers' bleaching and oxidation budgets against imported H₂O₂ and, in some applications, against chlorine-based chemistry.
Customer types and end-markets
Per company and S&P-sourced descriptions, NPL's H₂O₂ is used for: textile bleaching; paper and pulp bleaching; sugar bleaching; non-edible oil bleaching; chemical synthesis (oxidation reactions, dye oxidation, polymer manufacture, starch modification); water and effluent treatment and broader environmental control (refineries including Cochin Refineries and Reliance Petroleum adopted H₂O₂ for wastewater applications in 2002–03); metallurgy and mining; electronics; cosmetics; pharmaceuticals (antiseptics); sterilisation; and antichlor applications.
Company's own description vs independent characterisation
Company's description (paraphrased from exchange summaries and annual report extracts): NPL presents itself as a specialist that derives value from manufacturing H₂O₂ for multiple applications; a pioneer in India's peroxygen chemicals, the largest H₂O₂ producer in the country, operating an integrated, modern AO plant at Kalyan to international quality standards, and also a supplier of peracetic acid and compressed hydrogen.
Independent characterisation: NPL is a price-taker in a structurally over-supplied domestic market. Since the expiry of Indian anti-dumping duties on H₂O₂ in 2022, imports have rebounded and industry analysts (Chemical Market Analytics/OPIS, 2023) describe the Indian market as remaining in surplus. NPL's earnings therefore swing with spread (H₂O₂ realisation minus gas and raw-material cost) rather than volume growth. Its distinctive features are (i) the largest single-site domestic capacity, (ii) captive hydrogen, (iii) a 70-year customer franchise, and (iv) an unusually liquid balance sheet (₹70 Cr cash and investments vs ₹13 Cr debt including leases at FY2026), set against (v) single-plant concentration risk, (vi) micro-cap illiquidity, and (vii) recent governance/reporting noise (deferred board meetings, revised audited accounts, CFO turnover).
Strategy
Stated strategy themes
NPL does not publish investor presentations, hold earnings calls, or issue medium-term targets. The strategic themes that can be drawn from its filings and annual-report extracts are:
-
Domestic leadership through scale: capacity was expanded in 2019–20 with the explicit aim of improving market share and overall performance (company statement at the time of the shutdown).
-
Specialist positioning: the company frames itself as a specialist that derives value from H₂O₂ across multiple applications — implying an application-development rather than cost-only strategy.
-
Corporate simplification: the 2023 composite scheme separated the operating chemical business (NPL) from the investment holdings (Naperol), giving each its own listing and capital allocation.
-
Shareholder returns: dividends of ₹12.50 (FY2024) and ₹7 (FY2026), suspended in the loss year FY2025.
-
Responsible Care / management systems: certifications to ISO 9001, ISO 14001, OHSAS 18001, ISO 50001 and RC 14001, plus the Indian Chemical Council's Responsible Care logo (predecessor disclosures, 2019–2021).
Initiatives in the last 24 months
| Date | Initiative | Detail | Status |
|---|---|---|---|
| Jul 2024 | Independent listing | BSE listing of NPL (544205) completes the demerger | Completed |
| FY2025–FY2026 | Capex restraint | Capex cut to ₹4.9 Cr (FY2025) and ₹4.4 Cr (FY2026) from ₹14.6 Cr (FY2024) | Ongoing |
| FY2026 | Treasury redeployment | ₹19.5 Cr net purchase of investment securities; ₹8.65 Cr placed in long-term investments | Completed |
| FY2026 | Debt elimination | Long-term borrowings reduced to nil (excluding current portion ₹3.5 Cr and leases) | Near-complete |
| Apr 2026 | Dividend reinstatement | ₹7/share final dividend for FY2026 | Paid after 29 Sep 2026 AGM approval |
| Oct 2026 | Board/KMP reshuffle | Change in directors and KMP; director resignation | — |
No transformation programme, new-product launch, capacity expansion, green-hydrogen project, cost programme with stated targets, or formal ESG targets have been announced in sources reviewed.
Management guidance / medium-term targets
Not publicly disclosed. The company provides no numerical guidance.
Products & Services
All products sit within the single peroxygen segment. No pricing schedules are publicly disclosed; realisations are market-linked.
Hydrogen Peroxide 50% w/w (flagship)
Description: Concentrated aqueous solution containing 50% H₂O₂ by weight — NPL's standard commercial product.
Specifications/capabilities: Produced by AO process; technical and food grades; strong oxidiser that decomposes to water and oxygen, marketed as an environmentally "clean" oxidant.
Target customers: Textile processors, pulp and paper mills, chemical manufacturers, refineries (effluent), mining/metallurgy.
Launch/latest version: Commercial H₂O₂ since 1956; AO-based production at Kalyan; latest capacity step-up commissioned early 2020.
Pricing model: Not publicly disclosed; spot/contract, import-parity linked.
Hydrogen Peroxide 35% w/w
Description: Lower-concentration grade for applications requiring safer handling or direct dosing (e.g., textile and water treatment).
Target customers: Smaller industrial users, distributors.
Pricing/launch year: Not publicly disclosed.
Hydrogen Peroxide 60% w/w
Description: Higher-strength grade reducing freight cost per unit of active oxygen; used in chemical synthesis and pulp bleaching.
Pricing/launch year: Not publicly disclosed.
Hydrogen Peroxide 70% w/w
Description: Highest commercial concentration offered; for specialised chemical synthesis and applications where water dilution must be minimised.
Pricing/launch year: Not publicly disclosed.
Food-grade Hydrogen Peroxide
Description: Grade meeting food-contact purity standards; used in aseptic packaging sterilisation, food processing and sugar bleaching.
Pricing/launch year: Not publicly disclosed.
Peracetic Acid
Description: Equilibrium mixture of H₂O₂ and acetic acid; a broad-spectrum disinfectant and sterilant.
Target customers: Food and beverage processors, dairy, healthcare/sterilisation, water treatment.
Launch year/pricing: Not publicly disclosed.
Compressed Hydrogen Gas
Description: Hydrogen from the captive hydrogen plant (set up 1987) in excess of process needs, compressed and sold in cylinders/tube trailers.
Target customers: Hydrogenation users, glass, metallurgy, laboratories and electronics in the Mumbai–Pune industrial belt.
Pricing: Not publicly disclosed.
Legacy / discontinued lines (historical, for completeness)
The predecessor historically manufactured sodium perborate and other persalts (cited by Solvay in 2017) and, through a plastic-additives division, litharge and PVC stabilisers. These are not described in current company summaries and are presumed discontinued; current status not publicly disclosed.
Technical services
Application development and technical service have been part of the model since the 1979 Kalyan research centre (e.g., promoting H₂O₂ for refinery effluent and newsprint). These services are bundled with product sales and not separately monetised.
Financial Narrative
Basis of preparation
FY2022: predecessor National Peroxide Limited (BSE 500298), consolidated, which then included the investment activity later moved into Naperol (Capital Market/IIFL, 13 May 2022). It is the closest available proxy; it is not like-for-like.
FY2023: the demerged chemical business as presented in the listed company's comparatives (appointed date 1 Apr 2022) (Research360 standalone summary).
FY2024–FY2026: National Peroxide Limited, standalone.
FY2026: is shown in two versions: "as originally reported" (board approval 30 Apr 2026) and "revised" (S&P data updated after the 12 Aug 2026 revised audited results). The nature of the revision is not explained in sources available; the revised figures roughly halve FY2026 profit.
Income statement — 5 years (₹ Cr)
Sources: FY2022 — Capital Market via IIFL/Business Standard (13 May 2022); FY2022 EPS computed on 57.47 lakh shares; FY2023–FY2026 — Research360 standalone summary (FY2026 as originally reported); margins computed. FY2023 PBT includes an exceptional gain of ₹12.95 Cr (PBT before exceptional ₹40.55 Cr). FY2022 net profit exceeded PBT owing to tax credits.
Income statement — S&P standardised, 3 years (₹ Cr), with FY2026 revised
Source: S&P Global Market Intelligence via StockAnalysis.com (last updated 12 Aug 2026). FY2024 dividend ₹12.50 paid Aug 2024 (ex-date 20 Aug 2024); FY2025 — S&P shows no dividend declared; FY2026 — ₹7 final dividend (70%) recommended 30 Apr 2026, ex-date 22 Sep 2026.
FY2026 reconciliation — original vs revised (₹ Cr):
Sources: Original — Multibagg summary of 30 Apr 2026 filing (PAT ₹1,103.71 lakh) and Research360; Revised — S&P via StockAnalysis (Aug 2026). Note: one aggregator (Equitybulls, 3 May 2026) reported FY2026 "net profit" of ₹14.43 Cr and Q4 ₹10.66 Cr — these match the reported PBT figures and appear to be mislabelled; the EPS of ₹13.80 for Q4 FY2026 is consistent with Q4 PAT of ₹7.93 Cr. The exact cause and line items of the August revision are not publicly disclosed in sources reviewed and should be checked against the revised audit report on BSE.
Revenue CAGR: FY2022→FY2026 (predecessor-to-successor, not like-for-like): +6.4% p.a.; FY2023→FY2026 (like-for-like chemical business): –8.3% p.a.; FY2024→FY2026: –6.7% p.a. (analyst computation).
Quarterly trajectory (₹ Cr)
Sources: Screener (Q1FY24–Q1FY26 to two decimals); Fyers (Q2FY26–Q1FY27, rounded to ₹ Cr); Equitybulls (Q4FY26 revenue ₹87.06 Cr); Univest (Q1FY27 revenue ₹96 Cr, +44.1% YoY). Q4FY26 figures are as originally reported (pre-revision). Q3FY26 PAT ₹1.78 Cr; Q4FY26 PAT ₹7.93 Cr (original); Q1FY27 PAT reported at roughly ₹6–7 Cr (Univest headline: ~₹6 Cr, +642% YoY).
Balance sheet — 3 years (₹ Cr)
Source: S&P Global Market Intelligence via StockAnalysis.com (12 Aug 2026). FY2022–FY2023 balance sheets for the demerged business are not publicly disclosed in comparable form. Note: the large "comprehensive income & other" reserve (≈ ₹306.5 Cr) reflects the demerger-related capital/fair-value reserve rather than accumulated earnings; retained earnings were only ₹44.6 Cr at FY2026.
Cash flow — 3 years (₹ Cr)
Source: S&P via StockAnalysis.com. Note the FY2025 dividend paid (₹7.18 Cr) appears to reflect the ₹12.50/share FY2024 dividend paid in August 2024 net of TDS/IEPF timing, while FY2024's ₹10.06 Cr relates to the predecessor's dividend; the precise mapping is not disclosed. FY2026 OCF was boosted by ₹10.5 Cr of other operating-asset changes, including a ₹7.3 Cr rise in customer advances.
Ratio analysis (analyst computations unless stated)
Notes: FY2026 ratios use revised net income (₹5.82 Cr); on the originally reported ₹11.04 Cr, FY2026 ROE would be ≈ 3.1%. Inventory and payables days use S&P cost of revenue. S&P reports trailing-twelve-month (to Jun 2026) ROIC of 4.49%, interest coverage of 14.1x and debt/EBITDA of 0.33x, reflecting the strong Q1 FY2027.
Commentary — trends, inflections and drivers
Revenue. The like-for-like chemical business peaked at ₹375.87 Cr in FY2023, when post-COVID textile and paper restocking and the 150,000 MTPA plant's first full high-utilisation years coincided with firm prices; Q3 FY2023 alone delivered ₹115 Cr of sales (Equitymaster quarterly data, ₹1,152 M). Revenue then fell 11.4% in FY2024 and 13.8% in FY2025, a period that overlaps with the lapse of India's anti-dumping duty (2022) and a structurally long domestic market as imports from South-East Asia, Bangladesh and Korea returned. FY2026 revenue was flat (+1.0%) but the quarterly run-rate inflected sharply in the second half: Q4 FY2026 revenue of ₹87.06 Cr (+18% YoY) and Q1 FY2027 revenue of ~₹96 Cr (+44% YoY) are the highest since FY2023. Third-party price trackers show Asian H₂O₂ prices firming 4%–22% QoQ in calendar Q2 2026 on tight supply and raw-material shortages before softening in June, which is consistent with a price-led rather than volume-led recovery.
Margins. EBITDA margins compressed from 15.6% (FY2023) to 11.3% (FY2024) and 5.3% (FY2025) as realisations fell faster than costs. FY2026 shows a mix shift: raw-material cost fell sharply (₹141.2 Cr vs ₹200.4 Cr in FY2025, per Research360), but "miscellaneous/other" expenses more than doubled (₹99.5 Cr vs ₹45.7 Cr). That pattern is consistent with a reclassification of energy/utility costs or a change in input sourcing; the drivers are not explained in the sources reviewed. Gross margin (S&P) recovered from 27.7% to 31.7% and to 35.9% on a TTM-to-June-2026 basis.
Profitability. At the net level the business has earned below its cost of capital in every year since the demerger (S&P estimates WACC at ~12.1% vs ROIC of 0.9%–4.5%). FY2023's ₹39.5 Cr PAT was flattered by a ₹12.95 Cr exceptional gain. The FY2026 restatement (PAT ₹11.04 Cr → ₹5.82 Cr) is a material credibility event even if the underlying cause turns out to be technical.
Balance sheet. NPL is effectively unlevered: only ₹3.5 Cr of term debt remained at FY2026 (the ECB taken for the 2019–20 expansion is near-fully repaid), with ₹69.9 Cr of cash, liquid funds and trading securities. Net cash of ₹57.1 Cr equals 17% of market capitalisation. Depreciation (₹20 Cr p.a.) now exceeds capex (₹4–5 Cr p.a. in FY2025–FY2026) by 4–5x, so net block is shrinking ~5% a year — positive for FCF in the near term, but implying deferred maintenance or the absence of growth projects.
Cash conversion. OCF has exceeded net income in every year (FY2026 OCF ₹34.2 Cr vs PAT ₹5.8 Cr) because of the high non-cash depreciation charge. The cash conversion cycle lengthened from 48 to 59 days in FY2026, driven by a ₹5.6 Cr inventory build ahead of the stronger Q1 FY2027.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Group Entities
| Entity | Relationship to NPL | Notes |
|---|---|---|
Nowrosjee Wadia & Sons Ltd | Largest promoter (30.78%) | Wadia Group holding company |
Baymanco Investments Ltd | Promoter (20.38%) | Classified as foreign promoter; Simply Wall St aggregates this with Bombay Burmah (24.3%) — suggesting Baymanco is a Bombay Burmah group vehicle |
Macrofil Investments Ltd | Promoter (12.99%) | Subsidiary of Nowrosjee Wadia & Sons (per predecessor disclosures) |
The Bombay Burmah Trading Corporation Ltd | Promoter (3.90%) | CEO Rajiv Arora is also BBTCL's COO |
The Bombay Dyeing & Mfg. Co. Ltd | Promoter (1.06%) | Original 1954 JV partner |
Naperol Investments Ltd (BSE 500298) | Sister company (former parent shell) | Holds the pre-demerger investment business |
Subsidiaries of NPL | None disclosed | NPL reports standalone; aggregators show "consolidated" figures identical to standalone |
Results by Segment and Segment Margins & Growth (%)
| Segment | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Hydrogen peroxide & peroxygen products revenue (INR Cr) | 332.99 | 286.87 | 289.71 |
Segment operating profit before other income (INR Cr) | 37.59 | 15.21 | 31.19 |
Segment pre-tax profit, as originally reported (INR Cr) | 21.51 | -2.08 | 14.43 |
Segment operating margin (%) | 11.3 | 5.3 | 10.8 |
Contribution to total revenue (%) | 100 | 100 | 100 |
YoY revenue growth (%) | -11.4 | -13.8 | 1.0 |
Income Statement and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue from operations (INR Cr) | 225.94 | 375.87 | 332.99 | 286.87 | 289.71 |
Operating profit before other income, EBITDA proxy (INR Cr) | 17.01 | 58.51 | 37.59 | 15.21 | 31.19 |
Pre-tax profit, as reported (INR Cr) | 0.95 | 53.50 | 21.51 | -2.08 | 14.43 |
Net profit, as reported (INR Cr) | 5.43 | 39.50 | 16.79 | -2.25 | 11.04 |
EPS basic, as reported (INR) | 9.45 | 68.73 | 29.22 | -3.91 | 19.20 |
Operating margin, EBITDA proxy (%) | 7.53 | 15.57 | 11.29 | 5.30 | 10.77 |
Net margin (%) | 2.40 | 10.51 | 5.04 | -0.78 | 3.81 |
Income Statement and Per-Share Data (FY2024–FY2026)
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Revenue (INR Cr) | 333.0 | 286.9 | 289.7 |
Cost of revenue (INR Cr) | 222.7 | 207.5 | 197.8 |
Gross profit (INR Cr) | 110.3 | 79.4 | 91.9 |
Operating income / EBIT (INR Cr) | 18.3 | -4.9 | 3.5 |
EBITDA (INR Cr) | 36.7 | 14.5 | 23.4 |
Depreciation & amortisation for EBITDA (INR Cr) | 18.4 | 19.4 | 19.9 |
Interest expense (INR Cr) | 1.98 | 1.67 | 1.36 |
Pre-tax income (INR Cr) | 21.5 | -2.1 | 7.5 |
Income tax (INR Cr) | 4.7 | 0.2 | 1.7 |
Net income (INR Cr) | 16.8 | -2.2 | 5.8 |
EPS basic and diluted (INR) | 29.22 | -3.91 | 10.13 |
Dividend per share declared for the year (INR) | 12.5 | 0 | 7 |
Gross margin (%) | 33.13 | 27.67 | 31.71 |
EBIT margin (%) | 5.50 | -1.71 | 1.19 |
EBITDA margin (%) | 11.03 | 5.06 | 8.07 |
Net margin (%) | 5.04 | -0.78 | 2.01 |
Effective tax rate (%) | 21.96 | -8.20 | 22.20 |
Income Statement and Per-Share Data (FY2026 original–FY2026 revised)
| Metric | FY2026 original | FY2026 revised |
|---|---|---|
Revenue (INR Cr) | 289.71 | 289.71 |
Pre-tax profit (INR Cr) | 14.43 | 7.49 |
Net profit (INR Cr) | 11.04 | 5.82 |
EPS (INR) | 19.20 | 10.13 |
Income Statement
| Metric | Q1FY24 | Q2FY24 | Q3FY24 | Q4FY24 | Q1FY25 | Q2FY25 | Q3FY25 | Q4FY25 | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net revenue (INR Cr) | 79.52 | 81.79 | 83.64 | 88.03 | 73.99 | 77.02 | 62.16 | 73.70 | 66.66 | 68 | 69 | 87.06 | 96 |
Operating profit (INR Cr) | 10.11 | 9.03 | 9.42 | 9.03 | 10.21 | 4.12 | 3.23 | -2.35 | 4.82 | 6 | 8 | 16 | 14 |
Pre-tax profit (INR Cr) | 6.08 | 5.96 | 5.35 | 4.13 | 6.81 | 0.92 | -1.99 | -7.82 | 1.36 | 0.64 | 2 | 11 | 9 |
Balance Sheet and Per-Share Data
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Total assets (INR Cr) | 459.3 | 441.7 | 458.7 |
Cash and equivalents (INR Cr) | 8.61 | 12.93 | 18.80 |
Cash plus short-term investments and trading securities (INR Cr) | 51.74 | 49.67 | 69.85 |
Short-term borrowings incl. current portion of LT debt (INR Cr) | 3.46 | 3.49 | 3.52 |
Long-term borrowings (INR Cr) | 7.01 | 3.52 | 0 |
Lease liabilities, current plus non-current (INR Cr) | 9.28 | 9.04 | 9.20 |
Total debt incl. leases (INR Cr) | 19.74 | 16.05 | 12.71 |
Net debt, negative means net cash (INR Cr) | -32.00 | -33.63 | -57.13 |
Shareholders' equity (INR Cr) | 359.0 | 349.3 | 356.8 |
Goodwill (INR Cr) | 0 | 0 | 0 |
Other intangible assets (INR Cr) | 0.03 | 0.50 | 0.38 |
Property, plant and equipment, net (INR Cr) | 332.0 | 314.7 | 299.1 |
Inventory (INR Cr) | 33.85 | 32.49 | 38.07 |
Trade receivables (INR Cr) | 27.15 | 22.81 | 25.59 |
Trade payables (INR Cr) | 22.33 | 19.80 | 23.40 |
Working capital (INR Cr) | 79.15 | 84.20 | 88.75 |
Deferred tax liability (INR Cr) | 40.20 | 39.73 | 41.18 |
Book value per share (INR) | 624.67 | 607.73 | 620.85 |
Cash Flow and Margin Analysis (%)
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Operating cash flow (INR Cr) | 36.40 | 18.67 | 34.24 |
Capital expenditure (INR Cr) | 14.63 | 4.89 | 4.45 |
Free cash flow (INR Cr) | 21.77 | 13.78 | 29.79 |
Dividends paid (INR Cr) | 10.06 | 7.18 | 0 |
Share buybacks (INR Cr) | 0 | 0 | 0 |
Long-term debt repaid (INR Cr) | 3.95 | 3.77 | 4.00 |
Net purchase(-)/sale(+) of investment securities (INR Cr) | -3.62 | 1.87 | -19.51 |
Interest paid (INR Cr) | 2.68 | 1.59 | 1.36 |
FCF margin (%) | 6.54 | 4.80 | 10.28 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Return on equity (%) | 4.68 | -0.63 | 1.65 |
Return on assets (%) | 3.66 | -0.50 | 1.29 |
ROIC, after-tax EBIT over invested capital (%) | 4.4 | -1.5 | 0.9 |
Current ratio (x) | 2.93 | 3.30 | 2.77 |
Debt to equity incl. leases (x) | 0.055 | 0.046 | 0.036 |
Net debt to EBITDA (x) | -0.87 | -2.32 | -2.44 |
Interest coverage, EBIT over interest (x) | 9.2 | -2.9 | 2.5 |
Asset turnover (x) | 0.73 | 0.65 | 0.63 |
Days sales outstanding | 30 | 29 | 32 |
Days inventory outstanding | 55 | 57 | 70 |
Days payables outstanding | 37 | 35 | 43 |
Cash conversion cycle (days) | 48 | 51 | 59 |
Revenue by Region
| Region | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Total revenue, predominantly India (INR Cr) | 332.99 | 286.87 | 289.71 |
Valuation Snapshot
| Metric | Value | Date / Source |
|---|---|---|
Last close (INR) | 585.05 | 6 Oct 2026, StockAnalysis |
52-week change (%) | -1.07 | S&P, 6 Oct 2026 |
Price on 16 Aug 2024 (INR), early post-listing | 929.15 | ICICIdirect |
Change since Aug 2024 (%) | -37.0 | Analyst computation |
52-week low (INR) | 350.00 | Emkay, Mar 2026 |
52-week high, as of Mar 2026 (INR) | 770.00 | Emkay |
50-day / 200-day moving average (INR) | 608.66 / 516.15 | S&P, Oct 2026 |
Beta, 5-year (x) | 1.46 | S&P |
Average daily volume, 20-day (shares) | 1,028 | S&P |
3-year and 5-year returns | Not applicable — listed 4 Jul 2024; predecessor (500298) history not comparable after demerger | — |
Share Price
| Metric | Aug2024 | Sep2025 | Dec2025 | Mar2026 | Jul2026 | Aug2026 | Oct2026 |
|---|---|---|---|---|---|---|---|
Share price (INR) | 929.15 | 601 | 482.90 | 350.85 | 563.35 | 642.65 | 585.05 |
Valuation Multiples
| Multiple | NPL |
|---|---|
Trailing P/E (x) | 20.07 |
EV/EBITDA, TTM (x) | 7.13 |
EV/Sales, TTM (x) | 0.87 |
P/B (x) | 0.93 |
P/FCF (x) | 11.29 |
FCF yield (%) | 8.86 |
Earnings yield (%) | 4.98 |
Per-Share Data and Returns & Leverage Ratios (%)
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Dividend per share (INR) | 12.5 | 0 | 7 |
Payout ratio on reported EPS (%) | 42.8 | 0 | 36.5 |
Analyst Conclusions
Management guidance and consensus
No management guidance is issued and no sell-side consensus exists. The next reporting event is Q2 FY2027 results (S&P estimates around 29 Oct 2026).
Bull case (grounded in the data)
-
Cyclical upturn is already visible: revenue has risen for three consecutive quarters (₹68 Cr → ₹69 Cr → ₹87 Cr → ₹96 Cr), and Q1 FY2027 PBT of ~₹9 Cr annualises to ~₹36 Cr — above FY2024's ₹21.5 Cr. Sustained, this implies EPS in the ₹45–50 range and a P/E near 12x at ₹585.
-
Asset backing limits downside: the market values the company at 0.93x book, while net cash (₹57 Cr) represents ~17% of market cap and the EV of ₹277 Cr is below the net book value of plant (₹299 Cr) for India's largest H₂O₂ facility.
-
Strong FCF with no capex need: FY2026 FCF of ₹29.8 Cr (8.9% FCF yield) and nil long-term debt give room to raise dividends or buy back stock.
Bear case (grounded in the data)
-
Structural oversupply: the domestic market has been in surplus since the 2022 duty lapse; ROE has not exceeded 4.7% since FY2023 and the business destroys value versus a ~12% cost of capital.
-
Credibility discount is warranted: audited FY2026 results were revised within four months (PAT roughly halved), two board meetings were cancelled or deferred in 2026, the CFO resigned, and further KMP changes followed on 1 Oct 2026 — all without public explanation in available sources.
-
Price momentum may already be rolling over: H₂O₂ prices softened in June 2026 in both Asia and the US; with gas-based hydrogen, NPL is a high-cost marginal producer relative to chlor-alkali competitors, so any price correction compresses margins fastest at NPL.
Catalysts and monitorables (next 12 months)
| Catalyst / monitorable | Why it matters | Timing |
|---|---|---|
| Q2 FY2027 results | Tests whether Q1 revenue/margin step-up is sustained | ~Late Oct / Nov 2026 |
| Explanation of FY2026 revision | Determines whether the issue is one-off/technical or systemic | Revised audit report (BSE, 12 Aug 2026); FY2026 Annual Report |
| Identity and calibre of new KMP/directors (1 Oct 2026) | Governance quality, especially CFO | Immediate |
| Domestic H₂O₂ realisations and import volumes | Primary earnings driver | Monthly |
| Any anti-dumping petition by Indian producers | Could restore pricing power | Unpredictable |
| Natural gas/LNG price trend | Primary cost driver | Ongoing |
| Capital allocation (dividend, buyback, capex) | Use of ₹70 Cr liquidity | FY2027 results (Apr–May 2027) |
| Competitive capacity additions in Gujarat | Supply overhang | Ongoing |
Concluding analyst verdict
National Peroxide Limited is a strategically important but economically mediocre asset: India's largest hydrogen peroxide plant, owned by a patient promoter group, generating cash but earning returns well below its cost of capital through a full cycle. The 2023 demerger cleanly isolated the chemical business, and the July 2024 listing gave investors direct exposure to it — yet the stock has since lost more than a third of its early post-listing value, bottoming at ₹351 in March 2026 before recovering to ~₹585.
The near-term data are genuinely encouraging. Quarterly revenue has climbed from a ₹67 Cr trough to ~₹96 Cr in Q1 FY2027, gross margins have widened to ~36% on a trailing basis, and the balance sheet is close to unlevered with ₹70 Cr of liquid assets. At 0.93x book, ~7x trailing EV/EBITDA and an ~9% FCF yield, the valuation embeds little optimism.
Against this, three factors justify a substantial discount. First, the industry is structurally long in India and NPL's gas-based hydrogen leaves it on the higher-cost side of the domestic curve, so upturns may be brief. Second, the August 2026 restatement of audited FY2026 profit, coupled with deferred board meetings and repeated KMP changes, undermines confidence in reported numbers until explained. Third, extreme illiquidity and zero institutional ownership mean any re-rating depends almost entirely on promoter actions.
On balance, NPL screens as a deep-value, special-situation micro-cap rather than a quality compounder. The investment case hinges on (a) evidence that the H₂O₂ price recovery persists through Q2–Q3 FY2027, (b) a credible explanation of the FY2026 revision and stable finance leadership, and (c) a clear capital-return policy for surplus cash. Absent those, the stock is likely to remain anchored near book value. Investors should treat it as a cyclical option with asset backing, size positions for illiquidity, and verify all FY2026 figures against the revised audit report before relying on them.
The FY2025-26 Annual Report (filed 3 Sep 2026), the revised FY2026 audit report (12 Aug 2026) and the 1 Oct 2026 KMP filing on BSE should be consulted to fill remaining gaps (auditor name, segment/export split, CFO identity, director changes, BRSR metrics).*
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Tenure on NPL board | Background | Age | FY compensation |
|---|---|---|---|---|---|
Ness Nusli Wadia | Chairman, Non-Independent Non-Executive (Promoter) | Chairman since 26 Oct 2023; long-standing chairman of predecessor | Managing Director, Bombay Burmah Trading Corp.; director of Britannia, Bombay Dyeing; chairman of Naperol Investments; Wadia hospitals and Ness Wadia Foundation trustee; born 30 May 1971 | 55 | Sitting fees/commission only; not disclosed in sources reviewed |
Rajiv Arora | Director & Chief Executive Officer | Since 25 Sep 2023 | Also COO of Bombay Burmah Trading Corp. since 13 Feb 2024 | 61 | ₹3.52 Cr total (≈96% salary) per S&P/Simply Wall St |
Parvathi Menon | Independent Non-Executive Director | — | — | — | Sitting fees; not disclosed |
Jaivir Singh | Independent Non-Executive Director | — | — | — | Sitting fees; not disclosed |
Dr. (Ms.) Minnie Bodhanwala | Non-Independent Non-Executive Director | — | Wadia Group nominee; co-trustee with Ness Wadia of the Regal Miles Trust (a promoter-group entity) | — | — |
“—” = not publicly disclosed.
Governance Detail
| Role | Name | Notes |
|---|---|---|
CEO | Rajiv Arora | Dual role with BBTCL |
Governance Detail (Annual)
| Category | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|
Promoters and promoter group (%) | 70.76 | 70.76 | 70.76 | 70.76 |
Foreign institutional investors (%) | 0 | 0 | 0 | 0 |
Mutual funds (%) | 0 | 0 | 0 | 0 |
Other domestic institutions (%) | 0.01 | 0.01 | 0.01 | 0.01 |
Retail and other public (%) | 29.22 | 29.22 | 29.23 | 29.23 |
Major Shareholders
| Rank | Holder | Shares | Stake (%) |
|---|---|---|---|
| 1 | Nowrosjee Wadia & Sons Ltd | 1,769,125 | 30.78 |
| 2 | Baymanco Investments Ltd | 1172000 (approx.) | 20.38 |
| 3 | Macrofil Investments Ltd | 746,609 | 12.99 |
| 4 | The Bombay Burmah Trading Corp. Ltd | 224000 (approx.) | 3.90 |
| 5 | The Bombay Dyeing & Mfg. Co. Ltd | 61,000 | 1.06 |
| 6 | Ben Nevis Investments Ltd | 51,500 | 0.90 |
| 7 | Investor Education and Protection Fund | 27,413 | 0.48 |
| 8 | Varnilam Investments & Trading Co. Ltd | 16,750 | 0.29 |
| 9 | Nusli Neville Wadia | 16,325 | 0.28 |
| 10 | Estate of Dina Neville Wadia | 5,250 | 0.09 |
Competitive Landscape
Key Competitors
| Competitor | Country | Relevance to NPL | H₂O₂ capacity / scale (where available) |
|---|---|---|---|
Gujarat Alkalies & Chemicals Ltd (GACL) | India | Largest domestic rival; chlor-alkali producer with by-product hydrogen at Vadodara and Dahej | 54,120 MTPA on 100% basis (≈108,000 MTPA at 50%), per GACL investor presentation; expansions announced over time |
Indian Peroxide Ltd | India | Dahej, Gujarat plant commissioned Oct 2018 | 45,000 t/yr (concentration basis not specified) |
Asian Peroxide Ltd | India | Domestic producer (Tamil Nadu) | — |
Hindustan Organic Chemicals Ltd | India | Historical producer (Rasayani) | — |
Prospective entrants (Meghmani group, Chemplast Sanmar) | India | Reported interest in new H₂O₂ plants, typically leveraging chlor-alkali hydrogen | — |
Solvay | Belgium | Global leader; former NPL shareholder; 18 plants worldwide incl. Map Ta Phut, Thailand (world's largest H₂O₂ plant) | Global scale |
Evonik | Germany | Global top-3 H₂O₂ producer; Asian plants | Global scale |
Arkema | France | Global producer with Asian capacity | Global scale |
Mitsubishi Gas Chemical | Japan | Asian producer/exporter | — |
Korean, Taiwanese, Thai, Indonesian and Bangladeshi exporters | Asia | Principal sources of import competition (targets of India's 2017–22 anti-dumping duty) | — |
“—” = not publicly disclosed.
Peer Comparison FY2026
| Metric | NPL | GACL | Indian Peroxide | Asian Peroxide |
|---|---|---|---|---|
H₂O₂ capacity, 100% basis (MTPA) | 75,000 | 54,120 | 22,500 | 0 |
Listed status | BSE micro-cap | Listed (BSE/NSE) | Unlisted | Unlisted |



